Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

On Friday, Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety ...

WEDNESDAY, Sept. 11, 2024 (HealthDay News) -- An experimental weight-loss pill appears to help people quickly shed pounds, a new study says. People who took the drug amycretin lost up to 13% of ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Researchers found those on 50mg of amycretin lost 10.4% of their body weight, while those taking two doses of 50mg – the maximum tested – lost 13.1%. This is compared to an average loss of 1.1 ...

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

Amycretin is being developed for subcutaneous and oral administration. Shares of this Denmark-based company gained 2.95% on June 12, following the announcement.

Amycretin differs from other drugs though in also mimicking a second hormone, amylin, which is responsible for helping to regulate blood sugar levels and slowing gastric emptying, prompting the ...

Amycretin also works slightly differently than Eli Lilly’s Zepbound and Viking Therapeutics’ experimental VK-2735, which target GLP-1 and GIPR receptors. Following the release of the trial results, ...